Table 2.

The rates of peripheral neuropathy reported in clinical trials investigating MMAE-based ADCs

Drugs	Indications	No. of patients	Incidence (%)		Reference
			Any-grade	Grade 3 or 4
Brentuximab vedotin	Relapsed/refractory CD30-positive HL and ALCL	45	22%	0%	Anas Younes (2010)17
	Relapsed/refractory systemic ALCL	58	41%	12%	Barbara Pro (2012)18
	Relapsed/refractory CD30-positive NHL	35	–	9%	Steven Horwitz (2014)19
	CD30-positive B-cell lymphomas, including DLBCL and other B-cell lymph	68	26.5%	2.9%	Eric D. Jacobsen (2015)20
	CD30-positive mycosis fungoides or primary cutaneous ALCL	66	67％	9%	H Miles Prince (2017)21
	CD30-positive PTCLa	223	52%	4%	Steven Horwitz (2019)22
	Stage III or IV classic HLa	662	66%	1.6%	Stephen M. Ansell (2022)23
Polatuzumab vedotin	Relapsed/refractory B-cell NHL and CLL	45	27%	9%	Maria Corinna A Palanca-Wessels (2015)24
	Relapsed/refractory DLBCLa	39	43.6%	0%	Laurie H. Sehn (2020)25
	CD20-positive DLBCLa	435	52.9%	1.6%	H. Tilly (2022)26
Enfortumab vedotin	Locally advanced or metastatic UC who had previously received platinum-based chemotherapy and previously treated with PD-1 or PD-L1 inhibitors.	296	46.3%	5.1%	Thomas Powles (2021)27
	Locally advanced or metastatic UC previously treated with PD-1 or PD-L1 inhibitors	125	40%	2%	Evan Y Yu (2021): Cohort 128
	Locally advanced or metastatic UC previously treated with PD-1 or PD-L1 inhibitors	89	54%	7.9%	Evan Y Yu (2021): Cohort 228
Disitamab vedotin	HER2-positive locally advanced or mUC who previously failed at least one line of systemic chemotherapy	43	46.3%	2.3%	Xinan Sheng (2021)29
	HER2-positive locally advanced or metastatic gastric or gastroesophageal junction cancer who were under at least second-line therapy	125b	40%	3.2%	Zhi Peng (2021)30
Tisotumab vedotin	Relapsed, advanced, or metastatic cancer of the ovary, cervix, endometrium, bladder, prostate, esophagus, HNSCC or NSCLC	147	21%	1%	Johann S de Bono (2019)31
	Recurrent or metastatic cervical cancer	55	36%	4%	David S Hong (2020)32
	Recurrent or metastatic cervical cancer who had received no more than two prior systemic regimens	101	8%	2%	Robert L Coleman (2021)33
	Japanese patients with advanced solid malignancies	17	17.6%	0%	Kan Yonemori (2022)34

ALCL, anaplastic large-cell lymphoma; HL, Hodgkin’s lymphoma; PTCL, peripheral T cell cell lymphomas; NHL, non-Hodgkin lymphomas; CLL, chronic lymphocytic leukemia; DLBCL, diffuse large B-cell lymphoma; UC, urothelial carcinoma; NSCLC, non-small-cell lung cancer; HNSCC, head and neck squamous cell carcinoma.

^aCombination with chemotherapy.

^bDescribed as hypoesthesia.